 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boston Scientific/Axonics merger to close in 2H24 as FTC seeks more info...

Boston Scientific/Axonics merger to close in 2H24 as FTC seeks more info

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Axonics Inc (AXNX), where a total of 5,694 contracts have traded so far, representing...

Noteworthy Thursday Option Activity: AXNX, ABBV, ROKU

This is a signal that AXNX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Axonics (AXNX, $69.17) RSI Indicator left the overbought zone on April 01, 2024

Axonics Modulation Technologies (AXNX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings...

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

This is a signal that AXNX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Axonics (AXNX, $68.92) Stochastic Oscillator left the overbought zone on March 26, 2024

Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results...

Axonics Stockholders Approve Merger Agreement with Boston Scientific

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Axonics provides update on inter partes review proceedings

Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics...

Axonics Provides Update on Inter Partes Review Proceedings

Axonics, Inc. (NASDAQ:AXNX  Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling...

Short Interest in Axonics, Inc. (NASDAQ:AXNX) Expands By 6.4%

This is a Bullish indicator signaling AXNX's price could rise from here. Traders may explore going long the stock or buying call options...

Axonics (AXNX, $68.7) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 19, 2024

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Volume (M)	608,291.00
52-Wk High	$69.68
52-Wk Low	$47.59

AXNX Axonics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals